Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Declines By 69.1%

SciSparc Ltd. (NASDAQ:SPRC) was the target of a significant decrease in short interest in December. As of December 15th, there was short interest totaling 57,651 shares, a decrease of 69.1% from the November 30th total of 186,467 shares. Currently, 10.9% of the company’s stock are short sold. Based on an average daily volume of 1,586,485 shares, the days-to-cover ratio is currently 0.0 days. Based on an average daily volume of 1,586,485 shares, the days-to-cover ratio is currently 0.0 days. Currently, 10.9% of the company’s stock are short sold.

SciSparc Stock Performance

SPRC stock opened at $1.39 on Thursday. The company’s 50 day moving average price is $2.56 and its 200 day moving average price is $4.31. SciSparc has a fifty-two week low of $1.35 and a fifty-two week high of $37.59.

SciSparc (NASDAQ:SPRC) last posted its quarterly earnings results on Tuesday, November 18th. The company reported ($3.08) EPS for the quarter. The business had revenue of $0.23 million for the quarter.

Wall Street Analysts Forecast Growth

SPRC has been the subject of a number of research reports. Wall Street Zen upgraded shares of SciSparc to a “sell” rating in a report on Saturday, September 13th. Weiss Ratings restated a “sell (e+)” rating on shares of SciSparc in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, SciSparc presently has a consensus rating of “Sell”.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.